Understanding the Upcoming INmune Bio Webinar on EMACC
INmune Bio Inc. (NASDAQ: INMB), a pioneering firm in the domain of inflammation and immunology, is excited to announce an upcoming webinar titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials," scheduled for November 7, 2024, at 1 PM ET. This informative session is designed to delve into the innovative EMACC system and its vital role in evaluating cognitive changes in patients with early Alzheimer's Disease (AD).
What is EMACC?
The Early and Mild Alzheimer’s Cognitive Composite (EMACC) is a robust cognitive metric that includes standardized neuropsychological assessments. It serves as an exceptional tool in clinical settings, particularly for trials focusing on early-stage Alzheimer’s patients. The EMACC is aimed at providing a more objective approach to measuring cognitive changes compared to traditional methods.
Insights from Leading Experts
The webinar will feature industry thought leaders including Dr. Judith Jaeger, President of CognitionMetrics and a key figure in the development of EMACC, and CJ Barnum, VP of CNS Drug Development at INmune Bio. Their insights will cover not only the intricacies of the EMACC but also the broader regulatory landscape influencing Alzheimer’s treatment development.
The Importance of Accurate Measurement
According to Dr. Jaeger, “The CDR was originally crafted to diagnose AD and determine the progression of the disease. In clinical trials, however, the focus shifts from diagnosis to measuring cognitive change.” This change in emphasis is crucial in distinguishing the effectiveness of treatments like XPro™ against placebo effects in clinical settings. The EMACC is designed to capture these subtle cognitive changes objectively, a leap forward in evaluating therapeutic efficacy.
What to Expect from the Webinar
The webinar will build upon findings that will be presented in a poster format at the upcoming Clinical Trial in Alzheimer’s Disease (CTAD) conference held in Madrid. This presentation underlines the significance of EMACC in displaying cognitive changes in a Phase II trial, enhancing the scientific foundations of Alzheimer’s treatment methodologies.
Enhancing Clinical Trial Efficiency
CJ Barnum emphasizes the revolutionary potential of the EMACC, stating that improved cognitive assessments can lead to shorter clinical trials. This not only alleviates burdens for participating patients but also reduces financial strains on investors, truly making a difference in the drug development landscape.
Registration Information
For those interested in participating, here are the registration details:
Date: November 7, 2024
Time: 1:00 PM Eastern Time
Webcast Registration: Join us to learn more about EMACC and its pivotal role in the fight against Alzheimer’s. Registration can be completed through the INmune Bio website.
INmune Bio’s Commitment to Alzheimer’s Research
Currently, INmune Bio is conducting a randomized Phase II trial to investigate the effects of its treatment XPro™ in patients suffering from Early AD. This innovative trial is crucial as it targets participants with neuroinflammation—a condition known to contribute to cognitive decline. By focusing on the underlying causes of cognitive impairment, INmune Bio aims to deliver better therapeutic outcomes.
Discover More about EMACC
The EMACC has proven its efficacy in past clinical assessments, showcasing significant relationships with biological indicators of inflammation that correlate with Alzheimer’s progression. This empirically validated measure enhances the rigor of clinical trials, thus contributing valuable data towards finding effective treatments.
About INmune Bio Inc.
INmune Bio, Inc. is publicly traded on NASDAQ under the ticker symbol INMB. The company is dedicated to harnessing the innate immune system to develop innovative therapies for diseases, including cancer and neurodegenerative disorders. They've developed a unique product pipeline that shows promise for multiple health conditions, including Mild Alzheimer's Disease and treatment-resistant depression.
Frequently Asked Questions
What is the purpose of the EMACC?
The EMACC measures cognitive changes objectively in early Alzheimer's patients, offering a more precise evaluation than traditional methods.
Who are the speakers for the upcoming webinar?
The webinar will feature Dr. Judith Jaeger from CognitionMetrics and CJ Barnum from INmune Bio, who will share insights on EMACC and its clinical implications.
How can I register for the webinar?
You can register for the webinar by visiting the INmune Bio website on the date of the event.
What is XPro™ and its significance?
XPro™ is a therapeutic candidate currently being tested in clinical trials for treating Early Alzheimer's Disease, aiming to reduce neuroinflammation.
What impact does EMACC have on drug development?
EMACC significantly enhances the assessment of cognitive changes, potentially leading to shorter, more efficient clinical trials in drug development.
